• Explore /
  • Poster
  • / Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intrahepatic injection of OrienX010 in stage IV melanoma with liver metastases.

Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intrahepatic injection of OrienX010 in stage IV melanoma with liver metastases.

Abstract Poster

Authors

null

Chuanliang Cui

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China

Chuanliang Cui , Bin Lian , Yue Yang , Shanshan Yin , Yue Cong , Xuan Wang , Lu Si , Zhihong Chi , Xinan Sheng , Yan Kong , Lili Mao , Li Zhou , Bixia Tang , Xieqiao Yan , Xue Bai , Siming Li , Juan Li , Caili Li , Xiaoting Wei , Jun Guo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04206358

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9564)

DOI

10.1200/JCO.2023.41.16_suppl.9564

Abstract #

9564

Poster Bd #

327

Abstract Disclosures

Similar Posters

First Author: Chuanliang Cui

First Author: Jun Guo

First Author: Mohammad Jad Moussa

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.

Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.

First Author: Yasunobu Ishizuka